{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:47:29Z","timestamp":1770968849590,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Specialized Research Fund for the National Natural Science Foundation of China","award":["31300765"],"award-info":[{"award-number":["31300765"]}]},{"name":"Specialized Research Fund for the National Natural Science Foundation of China","award":["81301803"],"award-info":[{"award-number":["81301803"]}]},{"DOI":"10.13039\/501100013286","name":"Specialized Research Fund for the Doctoral Program of Higher Education","doi-asserted-by":"crossref","award":["20120061120025"],"award-info":[{"award-number":["20120061120025"]}],"id":[{"id":"10.13039\/501100013286","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Jilin Province Science and Technology Development Program","award":["20130522006JH"],"award-info":[{"award-number":["20130522006JH"]}]},{"name":"National Science and Technology Major Project of the Ministry of Science and Technology of China","award":["2014ZX09304314-001"],"award-info":[{"award-number":["2014ZX09304314-001"]}]},{"name":"National Science and Technology Major Project of the Ministry of Science and Technology of China","award":["2012ZX10001009-002"],"award-info":[{"award-number":["2012ZX10001009-002"]}]},{"DOI":"10.13039\/100007595","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["JCKY-QKJC03"],"award-info":[{"award-number":["JCKY-QKJC03"]}],"id":[{"id":"10.13039\/100007595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.vaccine.2016.04.045","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T02:30:01Z","timestamp":1461983401000},"page":"2648-2655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model"],"prefix":"10.1016","volume":"34","author":[{"given":"Haihong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenlu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3047-2354","authenticated-orcid":false,"given":"Fangfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenzhen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"July (7)","key":"10.1016\/j.vaccine.2016.04.045_bib0170","first-page":"367","article-title":"Immunotherapy of cancer: from vision to standard clinical practice","volume":"130","author":"Huber","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2016.04.045_bib0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrc2293","article-title":"Survivin, cancer networks and pathway-directed drug discovery","volume":"8","author":"Altieri","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"April (16)","key":"10.1016\/j.vaccine.2016.04.045_bib0180","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.vaccine.2011.01.115","article-title":"Altered decamer and nonamer from an HLA-A0201-restricted epitope of survivin differentially stimulate T-cell responses in different individuals","volume":"29","author":"Bernatchez","year":"2011","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.vaccine.2016.04.045_bib0185","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.7314\/APJCP.2012.13.11.5557","article-title":"Correlation between auto-antibodies to survivin and MUC1 variable number tandem repeats in colorectal cancer","volume":"13","author":"Wang","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"issue":"April (4)","key":"10.1016\/j.vaccine.2016.04.045_bib0190","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00262-013-1516-5","article-title":"Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors","volume":"63","author":"Lennerz","year":"2014","journal-title":"Cancer Immunol Immunother"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2016.04.045_bib0195","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00262-012-1296-3","article-title":"DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model","volume":"61","author":"Zhang","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2016.04.045_bib0200","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.intimp.2013.04.015","article-title":"Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA\/MPL adjuvant in a murine melanoma model","volume":"17","author":"Wang","year":"2013","journal-title":"Int Immunopharmacol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2016.04.045_bib0205","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol Med"},{"issue":"September (7)","key":"10.1016\/j.vaccine.2016.04.045_bib0210","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1586\/14760584.7.7.951","article-title":"Strategies used for MUC1 immunotherapy: preclinical studies","volume":"7","author":"Tang","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2016.04.045_bib0215","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"September (17)","key":"10.1016\/j.vaccine.2016.04.045_bib0220","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"October (2)","key":"10.1016\/j.vaccine.2016.04.045_bib0225","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1432-1033.1995.607_2.x","article-title":"Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells","volume":"233","author":"Brockhausen","year":"1995","journal-title":"Eur J Biochem"},{"key":"10.1016\/j.vaccine.2016.04.045_bib0230","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1038\/oncsis.2013.16","article-title":"MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes","volume":"2","author":"Nath","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.vaccine.2016.04.045_bib0235","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1146\/annurev.ph.57.030195.003135","article-title":"Epithelial mucin genes","volume":"57","author":"Gendler","year":"1995","journal-title":"Annu Rev Physiol"},{"issue":"August (1)","key":"10.1016\/j.vaccine.2016.04.045_bib0240","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3816\/CLC.2001.n.018","article-title":"Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB\/IV non-small-cell lung cancer","volume":"3","author":"Palmer","year":"2001","journal-title":"Clin Lung Cancer"},{"issue":"November (10)","key":"10.1016\/j.vaccine.2016.04.045_bib0245","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.4049\/jimmunol.155.10.4766","article-title":"Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin","volume":"155","author":"Domenech","year":"1995","journal-title":"J Immunol"},{"issue":"September (7)","key":"10.1016\/j.vaccine.2016.04.045_bib0250","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1586\/14760584.7.7.963","article-title":"Strategies used for MUC1 immunotherapy: human clinical studies","volume":"7","author":"Tang","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"April\u2013May (4\u20135)","key":"10.1016\/j.vaccine.2016.04.045_bib0255","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.humimm.2008.02.006","article-title":"Induction of immune response and anti-tumor activities in mice with a DNA vaccine encoding human mucin 1 variable-number tandem repeats","volume":"69","author":"Zhang","year":"2008","journal-title":"Hum Immunol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2016.04.045_bib0260","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.3892\/or.2013.2950","article-title":"Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs","volume":"31","author":"Wang","year":"2014","journal-title":"Oncol Rep"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2016.04.045_bib0265","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00262-010-0822-4","article-title":"A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer","volume":"59","author":"Noguchi","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2016.04.045_bib0270","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-12-84","article-title":"Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients","volume":"12","author":"Iinuma","year":"2014","journal-title":"J Transl Med"},{"issue":"December (12)","key":"10.1016\/j.vaccine.2016.04.045_bib0275","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1940-6207.CAPR-13-0182","article-title":"A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease","volume":"6","author":"Disis","year":"2013","journal-title":"Cancer Prev Res"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2016.04.045_bib0280","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s00262-012-1296-3","article-title":"DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model","volume":"61","author":"Zhang","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.vaccine.2016.04.045_bib0285","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/cjoc.201090063","article-title":"Establishment of a tumor-bearing mouse model stably expressing human tumor antigens survivin and MUC1 VNTRs","volume":"28","author":"Zhang","year":"2012","journal-title":"Chem Res Chin Univ"},{"issue":"November (7528)","key":"10.1016\/j.vaccine.2016.04.045_bib0290","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"July (7)","key":"10.1016\/j.vaccine.2016.04.045_bib0295","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1172\/JCI26532","article-title":"Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake","volume":"116","author":"Loeffler","year":"2006","journal-title":"J Clin Investig"},{"issue":"September (41)","key":"10.1016\/j.vaccine.2016.04.045_bib0300","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1016\/j.vaccine.2013.07.055","article-title":"Generation of CTL responses against pancreatic cancer in vitro using dendritic cells co-transfected with MUC4 and survivin RNA","volume":"31","author":"Chen","year":"2013","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2016.04.045_bib0305","doi-asserted-by":"crossref","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","article-title":"Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial","volume":"9","author":"Hayton","year":"2014","journal-title":"PLOS ONE"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2016.04.045_bib0310","doi-asserted-by":"crossref","first-page":"e28185","DOI":"10.4161\/onci.28185","article-title":"Trial watch: DNA vaccines for cancer therapy","volume":"3","author":"Pol","year":"2014","journal-title":"Oncoimmunology"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2016.04.045_bib0315","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1517\/14712598.2015.993374","article-title":"Adenoviruses as gene\/vaccine delivery vectors: promises and pitfalls","volume":"15","author":"Appaiahgari","year":"2015","journal-title":"Expert Opin Biol Ther"},{"issue":"August (4)","key":"10.1016\/j.vaccine.2016.04.045_bib0320","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2174\/156652311796150363","article-title":"Advances and future challenges in adenoviral vector pharmacology and targeting","volume":"11","author":"Khare","year":"2011","journal-title":"Curr Gene Ther"},{"issue":"May (1)","key":"10.1016\/j.vaccine.2016.04.045_bib0325","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/2051013613480446","article-title":"The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence","volume":"1","author":"Ragonnaud","year":"2013","journal-title":"Ther Adv Vaccines"},{"issue":"June (Suppl. 2)","key":"10.1016\/j.vaccine.2016.04.045_bib0330","doi-asserted-by":"crossref","first-page":"B21","DOI":"10.1016\/j.vaccine.2014.12.082","article-title":"Beyond adjuvants: immunomodulation strategies to enhance T cell immunity","volume":"33","author":"Kamphorst","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16301992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T03:48:57Z","timestamp":1718509737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16301992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":33,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0264410X16301992"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}